1
|
van ‘t Land FR, Lau SP, de Koning W, Klaase L, Vink M, van Krimpen A, Dumas J, Vadgama D, Nuyttens JJ, Mustafa DAM, Stadhouders R, Willemsen M, Stubbs AP, Aerts JG, van Eijck CHJ. Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer. Cancers (Basel) 2022; 14:cancers14215299. [PMID: 36358718 PMCID: PMC9656492 DOI: 10.3390/cancers14215299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/24/2022] [Accepted: 10/25/2022] [Indexed: 11/24/2022] Open
Abstract
Simple Summary Around thirty-five percent of pancreatic cancer patients present with locally advanced pancreatic cancer. These patients are treated with chemotherapy, and sometimes (stereotactic)radiotherapy can be added to the treatment regimen. In this study, we treated patients with locally advanced pancreatic cancer, after standard-of-care treatment with chemotherapy, with stereotactic body radiotherapy and an immunological adjuvant called IMM-101. We hypothesized that this combination treatment has the potential to induce a potent anti-tumor immune response. This study aimed to investigate the safety and immuno-modulatory effects of the treatment in the peripheral blood. The treatment demonstrated to be safe. Immune monitoring of the peripheral blood showed transient lymphodepletion and signs of immune activation after treatment. Moreover, immune activation after treatment correlated with improved progression-free survival. Abstract Background: Patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy. In selected cases, stereotactic body radiotherapy (SBRT) can be added to the regimen. We hypothesized that adding an adjuvant containing a heat-killed mycobacterium (IMM-101) to SBRT may lead to beneficial immuno-modulatory effects, thereby improving survival. This study aims to investigate the safety of adding IMM-101 to SBRT and to investigate the immuno-modulatory effects of the combination treatment in the peripheral blood of LAPC patients. Methods: LAPC patients were treated with SBRT (40 Gy) and six intradermal vaccinations of one milligram IMM-101. The primary endpoint was an observed toxicity rate of grade 4 or higher. Targeted gene-expression profiling and multicolor flow cytometry were performed for longitudinal immune-monitoring of the peripheral blood. Results: Twenty patients received study treatment. No treatment-related adverse events of grade 4 or higher occurred. SBRT/IMM-101 treatment induced a transient decrease in different lymphocyte subsets and an increase in CD14+CD16−CD11b+HLA−DRlow myeloid-derived suppressor cells. Importantly, treatment significantly increased activated ICOS+, HLA-DR+ and Ki67+PD1+ T and NK cell frequencies. This was not accompanied by increased levels of most inhibitory markers, such as TIM-3 and LAG-3. Conclusions: Combination therapy with SBRT and a heat-killed mycobacterium vaccine was safe and had an immune-stimulatory effect.
Collapse
Affiliation(s)
- Freek R. van ‘t Land
- Department of Surgery, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Sai P. Lau
- Department of Surgery, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Willem de Koning
- Department of Pathology and Clinical Bioinformatics, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Larissa Klaase
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Madelief Vink
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Anneloes van Krimpen
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Jasper Dumas
- Department of Pathology, the Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Disha Vadgama
- Department of Pathology, the Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Joost J. Nuyttens
- Department of Radiation Oncology, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Dana A. M. Mustafa
- Department of Pathology, the Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Ralph Stadhouders
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
- Department of Cell Biology, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Marcella Willemsen
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Andrew P. Stubbs
- Department of Pathology and Clinical Bioinformatics, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Joachim G. Aerts
- Department of Pulmonary Medicine, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
- Erasmus MC Cancer Institute, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
| | - Casper H. J. van Eijck
- Department of Surgery, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
- Correspondence: ; Tel.: +31-10-703-38-54
| |
Collapse
|
2
|
Blaauboer A, Van Koetsveld PM, Mustafa DAM, Dumas J, Dogan F, Van Zwienen S, Van Eijck CHJ, Hofland LJ. Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer. Int J Oncol 2022; 61:97. [PMID: 35795999 DOI: 10.3892/ijo.2022.5387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Accepted: 04/06/2022] [Indexed: 11/06/2022] Open
Abstract
Resistance to gemcitabine is common and critically limits its therapeutic efficacy in patients with pancreatic cancer. Interferon‑beta (IFN‑β) induces numerous antitumor effects and synergizes with gemcitabine treatment. The immunomodulatory effects of this treatment regimen have not yet been described. In the present study, the antitumor effect of IFN‑β combined with gemcitabine was investigated in immune competent mice. Mouse KPC3 cells were used in all experiments. Treatment effects were determined with cell proliferation assay. Reverse transcription‑quantitative PCR was used to measure gene expression. For in vivo experiments, cells were subcutaneously injected in immune competent mice. For immune profiling, NanoString analysis was performed on tumor samples of treated and untreated mice. Baseline expression of Ifnar‑1 and Ifnar‑2c in KPC3 cells was 1.42±0.16 and 1.50±0.17, respectively. IC50 value of IFN‑β on cell growth was high (>1,000 IU/ml). IFN‑β pre‑treatment increased the in vitro response to gemcitabine (1.3‑fold decrease in EC50; P<0.001). In vivo, tumor size was not statistically significant smaller in mice treated with IFN‑β plus gemcitabine (707±92 mm3 vs. 1,239±338 mm3 in vehicle‑treated mice; P=0.16). IFN‑β alone upregulated expression of numerous immune‑related genes. This effect was less pronounced when combined with gemcitabine. For the first time, to the best of our knowledge, the immunomodulatory effects of IFN‑β, alone and combined with gemcitabine, in pancreatic cancer were reported. Prognostic markers for predicting effective responses to IFN‑β therapy are urgently needed.
Collapse
Affiliation(s)
- Amber Blaauboer
- Department of Surgery, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Peter M Van Koetsveld
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Dana A M Mustafa
- Department of Pathology, The Tumor Immuno‑Pathology Laboratory, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Jasper Dumas
- Department of Pathology, The Tumor Immuno‑Pathology Laboratory, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Fadime Dogan
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Suzanne Van Zwienen
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Casper H J Van Eijck
- Department of Surgery, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Leo J Hofland
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands
| |
Collapse
|
3
|
Lau SP, Klaase L, Vink M, Dumas J, Bezemer K, van Krimpen A, van der Breggen R, Wismans LV, Doukas M, de Koning W, Stubbs AP, Mustafa DAM, Vroman H, Stadhouders R, Nunes JB, Stingl C, de Miranda NFCC, Luider TM, van der Burg SH, Aerts JG, van Eijck CHJ. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. Eur J Cancer 2022; 169:20-31. [PMID: 35490565 DOI: 10.1016/j.ejca.2022.03.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 03/09/2022] [Accepted: 03/16/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis even after curative resection. Responses to immunotherapy are rare and related to inadequate T-cell priming. We previously demonstrated the potency of allogeneic lysate-dendritic cell (DC) vaccination in a preclinical model. Here we translate this concept to patients. METHODS In this phase I study, patients with resected PDAC were included when they demonstrated no radiologic signs of recurrence after standard-of-care treatment. Allogeneic tumour lysate-loaded autologous monocyte-derived DCs were injected at weeks 0, 2, 4 and at months 3 and 6. Objectives are feasibility, safety and immunogenicity of allogeneic tumour-DCs. The presence of tumour antigens shared between the vaccine and patient tumours was investigated. Immunological analyses were performed on peripheral blood, skin and tumour. RESULTS Ten patients were included. DC production and administration were successful. All patients experienced a grade 1 injection-site and infusion-related reaction. Two patients experienced a grade 2 fever and 1 patient experienced a grade 3 dyspnoea. No vaccine-related serious adverse events were observed. Shared tumour antigens were found between the vaccine and patient tumours. All evaluated patients displayed a vaccine-induced response indicated by increased frequencies of Ki67+ and activated PD-1+ circulating T-cells. In addition, treatment-induced T-cell reactivity to autologous tumour of study patients was detected. Seven out of ten patients have not experienced disease recurrence or progression at a median follow-up of 25 months (15-32 months). CONCLUSION Allogeneic tumour lysate-DC treatment is feasible, safe and induces immune reactivity to PDAC expressed antigens.
Collapse
Affiliation(s)
- S P Lau
- Department of Surgery, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands; Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - L Klaase
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - M Vink
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - J Dumas
- Department of Pathology, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - K Bezemer
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands; Amphera B.V., Onderwijsboulevard 225, 5223DE, 'S-Hertogenbosch, the Netherlands
| | - A van Krimpen
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - R van der Breggen
- Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, the Netherlands
| | - L V Wismans
- Department of Surgery, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - M Doukas
- Department of Pathology, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - W de Koning
- Department of Pathology, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands; Department of Pathology, Clinical Bioinformatics Unit, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - A P Stubbs
- Department of Pathology, Clinical Bioinformatics Unit, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - D A M Mustafa
- Department of Pathology, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - H Vroman
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - R Stadhouders
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands; Department of Cell Biology, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - J B Nunes
- Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, the Netherlands
| | - C Stingl
- Department of Neurology, Clinical and Cancer Proteomics, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - N F C C de Miranda
- Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, the Netherlands
| | - T M Luider
- Department of Neurology, Clinical and Cancer Proteomics, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - S H van der Burg
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, the Netherlands
| | - J G Aerts
- Department of Pulmonary Medicine, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands; Erasmus MC Cancer Institute, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands
| | - C H J van Eijck
- Department of Surgery, Erasmus University Medical Center, 'S-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands.
| |
Collapse
|
4
|
Broekhuizen M, Hitzerd E, van den Bosch TPP, Dumas J, Verdijk RM, van Rijn BB, Danser AHJ, van Eijck CHJ, Reiss IKM, Mustafa DAM. The Placental Innate Immune System Is Altered in Early-Onset Preeclampsia, but Not in Late-Onset Preeclampsia. Front Immunol 2022; 12:780043. [PMID: 34992598 PMCID: PMC8724430 DOI: 10.3389/fimmu.2021.780043] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 11/29/2021] [Indexed: 12/18/2022] Open
Abstract
Preeclampsia is a severe placenta-related pregnancy disorder that is generally divided into two subtypes named early-onset preeclampsia (onset <34 weeks of gestation), and late-onset preeclampsia (onset ≥34 weeks of gestation), with distinct pathophysiological origins. Both forms of preeclampsia have been associated with maternal systemic inflammation. However, alterations in the placental immune system have been less well characterized. Here, we studied immunological alterations in early- and late-onset preeclampsia placentas using a targeted expression profile approach. RNA was extracted from snap-frozen placenta samples (healthy n=13, early-onset preeclampsia n=13, and late-onset preeclampsia n=6). The expression of 730 immune-related genes from the Pan Cancer Immune Profiling Panel was measured, and the data were analyzed in the advanced analysis module of nSolver software (NanoString Technology). The results showed that early-onset preeclampsia placentas displayed reduced expression of complement, and toll-like receptor (TLR) associated genes, specifically TLR1 and TLR4. Mast cells and M2 macrophages were also decreased in early-onset preeclampsia compared to healthy placentas. The findings were confirmed by an immunohistochemistry approach using 20 healthy, 19 early-onset preeclampsia, and 10 late-onset preeclampsia placentas. We conclude that the placental innate immune system is altered in early-onset preeclampsia compared to uncomplicated pregnancies. The absence of these alterations in late-onset preeclampsia placentas indicates dissimilar immunological profiles. The study revealed distinct pathophysiological processes in early-onset and late-onset preeclampsia placentas and imply that a tailored treatment to each subtype is desirable.
Collapse
Affiliation(s)
- Michelle Broekhuizen
- Division of Neonatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, Netherlands.,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.,Division of Experimental Cardiology, Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Emilie Hitzerd
- Division of Neonatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, Netherlands.,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
| | | | - Jasper Dumas
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands.,The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Robert M Verdijk
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Bas B van Rijn
- Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - A H Jan Danser
- Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Casper H J van Eijck
- Department of Surgery, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Irwin K M Reiss
- Division of Neonatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Dana A M Mustafa
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands.,The Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
5
|
Chaarani B, Hahn S, Allgaier N, Adise S, Owens MM, Juliano AC, Yuan DK, Loso H, Ivanciu A, Albaugh MD, Dumas J, Mackey S, Laurent J, Ivanova M, Hagler DJ, Cornejo MD, Hatton S, Agrawal A, Aguinaldo L, Ahonen L, Aklin W, Anokhin AP, Arroyo J, Avenevoli S, Babcock D, Bagot K, Baker FC, Banich MT, Barch DM, Bartsch H, Baskin-Sommers A, Bjork JM, Blachman-Demner D, Bloch M, Bogdan R, Bookheimer SY, Breslin F, Brown S, Calabro FJ, Calhoun V, Casey BJ, Chang L, Clark DB, Cloak C, Constable RT, Constable K, Corley R, Cottler LB, Coxe S, Dagher RK, Dale AM, Dapretto M, Delcarmen-Wiggins R, Dick AS, Do EK, Dosenbach NUF, Dowling GJ, Edwards S, Ernst TM, Fair DA, Fan CC, Feczko E, Feldstein-Ewing SW, Florsheim P, Foxe JJ, Freedman EG, Friedman NP, Friedman-Hill S, Fuemmeler BF, Galvan A, Gee DG, Giedd J, Glantz M, Glaser P, Godino J, Gonzalez M, Gonzalez R, Grant S, Gray KM, Haist F, Harms MP, Hawes S, Heath AC, Heeringa S, Heitzeg MM, Hermosillo R, Herting MM, Hettema JM, Hewitt JK, Heyser C, Hoffman E, Howlett K, Huber RS, Huestis MA, Hyde LW, Iacono WG, Infante MA, Irfanoglu O, Isaiah A, Iyengar S, Jacobus J, James R, Jean-Francois B, Jernigan T, Karcher NR, Kaufman A, Kelley B, Kit B, Ksinan A, Kuperman J, Laird AR, Larson C, LeBlanc K, Lessov-Schlagger C, Lever N, Lewis DA, Lisdahl K, Little AR, Lopez M, Luciana M, Luna B, Madden PA, Maes HH, Makowski C, Marshall AT, Mason MJ, Matochik J, McCandliss BD, McGlade E, Montoya I, Morgan G, Morris A, Mulford C, Murray P, Nagel BJ, Neale MC, Neigh G, Nencka A, Noronha A, Nixon SJ, Palmer CE, Pariyadath V, Paulus MP, Pelham WE, Pfefferbaum D, Pierpaoli C, Prescot A, Prouty D, Puttler LI, Rajapaske N, Rapuano KM, Reeves G, Renshaw PF, Riedel MC, Rojas P, de la Rosa M, Rosenberg MD, Ross MJ, Sanchez M, Schirda C, Schloesser D, Schulenberg J, Sher KJ, Sheth C, Shilling PD, Simmons WK, Sowell ER, Speer N, Spittel M, Squeglia LM, Sripada C, Steinberg J, Striley C, Sutherland MT, Tanabe J, Tapert SF, Thompson W, Tomko RL, Uban KA, Vrieze S, Wade NE, Watts R, Weiss S, Wiens BA, Williams OD, Wilbur A, Wing D, Wolff-Hughes D, Yang R, Yurgelun-Todd DA, Zucker RA, Potter A, Garavan HP. Baseline brain function in the preadolescents of the ABCD Study. Nat Neurosci 2021; 24:1176-1186. [PMID: 34099922 PMCID: PMC8947197 DOI: 10.1038/s41593-021-00867-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Accepted: 04/30/2021] [Indexed: 02/05/2023]
Abstract
The Adolescent Brain Cognitive Development (ABCD) Study® is a 10-year longitudinal study of children recruited at ages 9 and 10. A battery of neuroimaging tasks are administered biennially to track neurodevelopment and identify individual differences in brain function. This study reports activation patterns from functional MRI (fMRI) tasks completed at baseline, which were designed to measure cognitive impulse control with a stop signal task (SST; N = 5,547), reward anticipation and receipt with a monetary incentive delay (MID) task (N = 6,657) and working memory and emotion reactivity with an emotional N-back (EN-back) task (N = 6,009). Further, we report the spatial reproducibility of activation patterns by assessing between-group vertex/voxelwise correlations of blood oxygen level-dependent (BOLD) activation. Analyses reveal robust brain activations that are consistent with the published literature, vary across fMRI tasks/contrasts and slightly correlate with individual behavioral performance on the tasks. These results establish the preadolescent brain function baseline, guide interpretation of cross-sectional analyses and will enable the investigation of longitudinal changes during adolescent development.
Collapse
Affiliation(s)
- B Chaarani
- Department of Psychiatry, University of Vermont, Burlington, VT, USA.
| | - S Hahn
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - N Allgaier
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - S Adise
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - M M Owens
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - A C Juliano
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - D K Yuan
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - H Loso
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - A Ivanciu
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - M D Albaugh
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - J Dumas
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - S Mackey
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - J Laurent
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - M Ivanova
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - D J Hagler
- University of California, San Diego, La Jolla, CA, USA
| | - M D Cornejo
- Institute of Physics UC, Pontificia Universidad Catolica de Chile, Pontificia, Chile
| | - S Hatton
- University of California, San Diego, La Jolla, CA, USA
| | - A Agrawal
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - L Aguinaldo
- University of California, San Diego, La Jolla, CA, USA
| | - L Ahonen
- University of Pittsburgh, Pittsburgh, PA, USA
| | - W Aklin
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - A P Anokhin
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - J Arroyo
- National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
| | - S Avenevoli
- National Institute of Mental Health, Bethesda, MD, USA
| | - D Babcock
- National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
| | - K Bagot
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - F C Baker
- SRI International, Menlo Park, CA, USA
| | - M T Banich
- University of Colorado, Boulder, CO, USA
| | - D M Barch
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - H Bartsch
- Haukeland University Hospital, Bergen, Norway
| | | | - J M Bjork
- Virginia Commonwealth University, Richmond, VA, USA
| | - D Blachman-Demner
- NIH Office of Behavioral and Social Sciences Research, Bethesda, MD, USA
| | - M Bloch
- National Cancer Institute, Bethesda, MD, USA
| | - R Bogdan
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | | | - F Breslin
- Laureate Institute for Brain Research, Tulsa, OK, USA
| | - S Brown
- University of California, San Diego, La Jolla, CA, USA
| | - F J Calabro
- University of Pittsburgh, Pittsburgh, PA, USA
| | - V Calhoun
- University of Colorado, Boulder, CO, USA
- Tri-institutional Center for Translational Research in Neuroimaging and Data Science, Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, GA, USA
| | | | - L Chang
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - D B Clark
- University of Pittsburgh, Pittsburgh, PA, USA
| | - C Cloak
- University of Maryland School of Medicine, Baltimore, MD, USA
| | | | - K Constable
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - R Corley
- University of Colorado, Boulder, CO, USA
| | | | - S Coxe
- Florida International University, Miami, FL, USA
| | - R K Dagher
- National Institute on Minority Health and Health Disparities, Bethesda, MD, USA
| | - A M Dale
- University of California, San Diego, La Jolla, CA, USA
| | - M Dapretto
- University of California, Los Angeles, CA, USA
| | | | - A S Dick
- Florida International University, Miami, FL, USA
| | - E K Do
- Virginia Commonwealth University, Richmond, VA, USA
| | - N U F Dosenbach
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - G J Dowling
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - S Edwards
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - T M Ernst
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - D A Fair
- Oregon Health & Science University, Portland, OR, USA
| | - C C Fan
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - E Feczko
- Oregon Health & Science University, Portland, OR, USA
| | | | | | - J J Foxe
- University of Rochester, Rochester, NY, USA
| | | | | | | | | | - A Galvan
- University of California, Los Angeles, CA, USA
| | - D G Gee
- Yale University, New Haven, CT, USA
| | - J Giedd
- University of California, San Diego, La Jolla, CA, USA
| | - M Glantz
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - P Glaser
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - J Godino
- University of California, San Diego, La Jolla, CA, USA
| | - M Gonzalez
- Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - R Gonzalez
- Florida International University, Miami, FL, USA
| | - S Grant
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - K M Gray
- Medical University of South Carolina, Charleston, SC, USA
| | - F Haist
- University of California, San Diego, La Jolla, CA, USA
| | - M P Harms
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - S Hawes
- Florida International University, Miami, FL, USA
| | - A C Heath
- University of California, San Diego, La Jolla, CA, USA
| | - S Heeringa
- University of Michigan, Ann Arbor, MI, USA
| | | | - R Hermosillo
- Oregon Health & Science University, Portland, OR, USA
| | - M M Herting
- University of Southern California, Los Angeles, CA, USA
| | - J M Hettema
- Virginia Commonwealth University, Richmond, VA, USA
| | - J K Hewitt
- University of Colorado, Boulder, CO, USA
| | - C Heyser
- University of California, San Diego, La Jolla, CA, USA
| | - E Hoffman
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - K Howlett
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - R S Huber
- University of Utah, Salt Lake City, UT, USA
| | - M A Huestis
- Thomas Jefferson University, Philadelphia, PA, USA
| | - L W Hyde
- University of Michigan, Ann Arbor, MI, USA
| | - W G Iacono
- University of Minnesota, Minneapolis, MN, USA
| | - M A Infante
- University of California, San Diego, La Jolla, CA, USA
| | - O Irfanoglu
- National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, USA
| | - A Isaiah
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - S Iyengar
- National Endowment for the Arts, Washington DC, USA
| | - J Jacobus
- University of California, San Diego, La Jolla, CA, USA
| | - R James
- Virginia Commonwealth University, Richmond, VA, USA
| | - B Jean-Francois
- National Institute on Minority Health and Health Disparities, Bethesda, MD, USA
| | - T Jernigan
- University of California, San Diego, La Jolla, CA, USA
| | - N R Karcher
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - A Kaufman
- National Cancer Institute, Bethesda, MD, USA
| | - B Kelley
- National Institute of Justice, Washington DC, USA
| | - B Kit
- National Heart, Lung, and Blood Institute, Bethesda, MD, USA
| | - A Ksinan
- Virginia Commonwealth University, Richmond, VA, USA
| | - J Kuperman
- University of California, San Diego, La Jolla, CA, USA
| | - A R Laird
- Florida International University, Miami, FL, USA
| | - C Larson
- University of Wisconsin, Milwaukee, WI, USA
| | - K LeBlanc
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - C Lessov-Schlagger
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - N Lever
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - D A Lewis
- University of Pittsburgh, Pittsburgh, PA, USA
| | - K Lisdahl
- University of Wisconsin, Milwaukee, WI, USA
| | - A R Little
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - M Lopez
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - M Luciana
- University of Minnesota, Minneapolis, MN, USA
| | - B Luna
- University of Pittsburgh, Pittsburgh, PA, USA
| | - P A Madden
- Department of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA
| | - H H Maes
- Virginia Commonwealth University, Richmond, VA, USA
| | - C Makowski
- University of California, San Diego, La Jolla, CA, USA
| | - A T Marshall
- Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - M J Mason
- University of Tennessee, Knoxville, TN, USA
| | - J Matochik
- National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
| | | | - E McGlade
- University of Utah, Salt Lake City, UT, USA
| | - I Montoya
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - G Morgan
- National Cancer Institute, Bethesda, MD, USA
| | - A Morris
- Oklahoma State University, Stillwater, OK, USA
| | - C Mulford
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - P Murray
- National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
| | - B J Nagel
- Oregon Health & Science University, Portland, OR, USA
| | - M C Neale
- Virginia Commonwealth University, Richmond, VA, USA
| | - G Neigh
- Virginia Commonwealth University, Richmond, VA, USA
| | - A Nencka
- Medical College of Wisconsin, Milwaukee, WI, USA
| | - A Noronha
- National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
| | - S J Nixon
- University of Florida, Gainesville, FL, USA
| | - C E Palmer
- University of California, San Diego, La Jolla, CA, USA
| | - V Pariyadath
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - M P Paulus
- Laureate Institute for Brain Research, Tulsa, OK, USA
| | - W E Pelham
- Florida International University, Miami, FL, USA
| | | | - C Pierpaoli
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA
| | - A Prescot
- University of Utah, Salt Lake City, UT, USA
| | - D Prouty
- SRI International, Menlo Park, CA, USA
| | | | - N Rajapaske
- National Institute on Minority Health and Health Disparities, Bethesda, MD, USA
| | | | - G Reeves
- University of Maryland School of Medicine, Baltimore, MD, USA
| | | | - M C Riedel
- Florida International University, Miami, FL, USA
| | - P Rojas
- Florida International University, Miami, FL, USA
| | - M de la Rosa
- Florida International University, Miami, FL, USA
| | | | - M J Ross
- University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - M Sanchez
- Florida International University, Miami, FL, USA
| | - C Schirda
- University of Pittsburgh, Pittsburgh, PA, USA
| | - D Schloesser
- NIH Office of Behavioral and Social Sciences Research, Bethesda, MD, USA
| | | | - K J Sher
- University of Missouri, Columbia, MO, USA
| | - C Sheth
- University of Utah, Salt Lake City, UT, USA
| | - P D Shilling
- University of California, San Diego, La Jolla, CA, USA
| | - W K Simmons
- Laureate Institute for Brain Research, Tulsa, OK, USA
| | - E R Sowell
- Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - N Speer
- University of Colorado, Boulder, CO, USA
| | - M Spittel
- NIH Office of Behavioral and Social Sciences Research, Bethesda, MD, USA
| | - L M Squeglia
- Medical University of South Carolina, Charleston, SC, USA
| | - C Sripada
- University of Michigan, Ann Arbor, MI, USA
| | - J Steinberg
- Virginia Commonwealth University, Richmond, VA, USA
| | - C Striley
- University of Florida, Gainesville, FL, USA
| | | | - J Tanabe
- University of Colorado, Boulder, CO, USA
| | - S F Tapert
- University of California, San Diego, La Jolla, CA, USA
| | - W Thompson
- University of California, San Diego, La Jolla, CA, USA
| | - R L Tomko
- Medical University of South Carolina, Charleston, SC, USA
| | - K A Uban
- University of California, Irvine, CA, USA
| | - S Vrieze
- University of Minnesota, Minneapolis, MN, USA
| | - N E Wade
- University of California, San Diego, La Jolla, CA, USA
| | - R Watts
- Yale University, New Haven, CT, USA
| | - S Weiss
- National Institute on Drug Abuse, Bethesda, MD, USA
| | - B A Wiens
- University of Florida, Gainesville, FL, USA
| | - O D Williams
- Florida International University, Miami, FL, USA
| | - A Wilbur
- SRI International, Menlo Park, CA, USA
| | - D Wing
- University of California, San Diego, La Jolla, CA, USA
| | - D Wolff-Hughes
- NIH Office of Behavioral and Social Sciences Research, Bethesda, MD, USA
| | - R Yang
- University of California, San Diego, La Jolla, CA, USA
| | | | - R A Zucker
- University of Michigan, Ann Arbor, MI, USA
| | - A Potter
- Department of Psychiatry, University of Vermont, Burlington, VT, USA
| | - H P Garavan
- Department of Psychiatry, University of Vermont, Burlington, VT, USA.
| |
Collapse
|
6
|
Huizer K, Zhu C, Chirifi I, Krist B, Zorgman D, van der Weiden M, van den Bosch TPP, Dumas J, Cheng C, Kros JM, Mustafa DA. Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. J Neuropathol Exp Neurol 2021; 79:863-872. [PMID: 32647861 DOI: 10.1093/jnen/nlaa067] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 05/12/2020] [Accepted: 06/11/2020] [Indexed: 12/13/2022] Open
Abstract
The expression of the matricellular protein periostin has been associated with glioma progression. In previous work we found an association of periostin with glioma angiogenesis. Here, we screen gliomas for POSTN expression and identify the cells that express periostin in human gliomas. In addition, we study the role of periostin in an in vitro model for angiogenesis. The expression of periostin was investigated by RT-PCR and by immunohistochemistry. In addition, we used double labeling and in situ RNA techniques to identify the expressing cells. To investigate the function of periostin, we silenced POSTN in a 3D in vitro angiogenesis model. Periostin expression was elevated in pilocytic astrocytoma and glioblastoma, but not in grade II/III astrocytomas and oligodendrogliomas. The expression of periostin colocalized with PDGFRβ+ cells, but not with OLIG2+/SOX2+ glioma stem cells. Silencing of periostin in pericytes in coculture experiments resulted in attenuation of the numbers and the length of the vessels formation and in a decrease in endothelial junction formation. We conclude that pericytes are the main source of periostin in human gliomas and that periostin plays an essential role in the growth and branching of blood vessels. Therefore, periostin should be explored as a novel target for developing anti-angiogenic therapy for glioma.
Collapse
Affiliation(s)
- Karin Huizer
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Changbin Zhu
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Ihsan Chirifi
- Laboratory for Experimental Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Bart Krist
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Denise Zorgman
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Marcel van der Weiden
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Thierry P P van den Bosch
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Jasper Dumas
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Caroline Cheng
- Laboratory for Experimental Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Johan M Kros
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Dana A Mustafa
- From the Laboratory for Tumor Immunopathology, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| |
Collapse
|
7
|
Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer 2020; 8:e000772. [PMID: 32690771 PMCID: PMC7373331 DOI: 10.1136/jitc-2020-000772] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/09/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment approach consisting of dendritic cell (DC) vaccination to prime tumor-specific T cells, and a strategy to reprogram the desmoplastic tumor microenvironment (TME) would be needed to break tolerance to these pancreatic cancers. As a proof-of-concept, we investigated the efficacy of combined DC vaccination with CD40-agonistic antibodies in a poorly immunogenic murine model of PDAC. Based on the rationale that mesothelioma and pancreatic cancer share a number of tumor associated antigens, the DCs were loaded with either pancreatic or mesothelioma tumor lysates. METHODS Immune-competent mice with subcutaneously or orthotopically growing KrasG12D/+;Trp53R172H/+;Pdx-1-Cre (KPC) PDAC tumors were vaccinated with syngeneic bone marrow-derived DCs loaded with either pancreatic cancer (KPC) or mesothelioma (AE17) lysate and consequently treated with FGK45 (CD40 agonist). Tumor progression was monitored and immune responses in TME and lymphoid organs were analyzed using multicolor flow cytometry and NanoString analyzes. RESULTS Mesothelioma-lysate loaded DCs generated cross-reactive tumor-antigen-specific T-cell responses to pancreatic cancer and induced delayed tumor outgrowth when provided as prophylactic vaccine. In established disease, combination with stimulating CD40 antibody was necessary to improve survival, while anti-CD40 alone was ineffective. Extensive analysis of the TME showed that anti-CD40 monotherapy did improve CD8 +T cell infiltration, but these essential effector cells displayed hallmarks of exhaustion, including PD-1, TIM-3 and NKG2A. Combination therapy induced a strong change in tumor transcriptome and mitigated the expression of inhibitory markers on CD8 +T cells. CONCLUSION These results demonstrate the potency of DC therapy in combination with CD40-stimulation for the treatment of pancreatic cancer and provide directions for near future clinical trials.
Collapse
Affiliation(s)
- Sai Ping Lau
- Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Nadine van Montfoort
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Priscilla Kinderman
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Melanie Lukkes
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Larissa Klaase
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Menno van Nimwegen
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Mandy van Gulijk
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Jasper Dumas
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Dana A M Mustafa
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Sanne L A Lievense
- Department of Pulmonary Medicine, Amphia Hospital, Breda, The Netherlands
| | - Christianne Groeneveldt
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Ralph Stadhouders
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Yunlei Li
- Clinical Bioinformatics Unit, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Andrew Stubbs
- Clinical Bioinformatics Unit, Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Koen A Marijt
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Heleen Vroman
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Sjoerd H van der Burg
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Joachim Aerts
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Thorbald van Hall
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - Floris Dammeijer
- Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | | |
Collapse
|
8
|
Lau SP, van Montfoort N, Kinderman P, Lukkes M, Dumas J, van Nimwegen M, Mustafa D, Vroman H, van Hall T, van der Burg SH, Aerts JG, Dammeijer F, van Eijck CH. Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15783 Background: Although immunotherapy yields striking results in various malignancies, results in pancreatic cancer have been disappointing. Both a highly immunosuppressive tumor microenvironment and a dense desmoplastic stroma have been found to prohibit proper T-cell infiltration in these tumors, thereby preventing immunotherapy efficacy. We hypothesize that a rational and translational multistep approach is needed to sensitize pancreatic cancer to immunotherapy. In an aggressive murine pancreatic ductal adenocarcinoma model, we assessed the effectiveness of dendritic cell (DC) vaccination in combination with αCD40 treatment, as these treatments are known to induce effector T cells and degrade stroma, respectively. Methods: Immune competent C57BL/6 mice were inoculated subcutaneously with pancreatic tumor cells (KPC3). Mice with established tumors were vaccinated with tumor-loaded monocyte derived DCs and consequently treated with αCD40 agonistic antibodies. Tumor sizes were monitored over time. Immune responses were determined by flow cytometry of cells in peripheral blood, spleen and tumor. NanoString Technologies were applied on tumor samples. Results: A significant delay in tumor growth was found in the combination therapy arm compared to untreated mice and mice treated with DCs or αCD40 alone. Monotherapy had no effect on tumor growth. Survival of mice treated with the combination therapy was also improved compared to untreated mice or mice treated with monotherapy (P < 0.001). Interim blood analysis showed significant increases in frequencies of activated and proliferating T cells in treated animals and those cells also displayed an effector memory phenotype. This was more pronounced for CD4 T cells in mice treated with DCs while αCD40 therapy induced a confined response in CD8 T cells. Increased frequencies of tumor infiltrating lymphocytes were found in all treated mice compared to untreated mice. mRNA expression analysis indicated less exhausted phenotype of intratumoral lymphoid cells in mice treated with DCs and αCD40 compared to monotherapy DCs or αCD40. Conclusions: These results demonstrate the potency of this novel form of combination immunotherapy and reveals a mechanistic insight into the requirements of effective immunotherapy in pancreatic cancer.
Collapse
|
9
|
Abbott D, Adderley P, Adeyemi A, Aguilera P, Ali M, Areti H, Baylac M, Benesch J, Bosson G, Cade B, Camsonne A, Cardman LS, Clark J, Cole P, Covert S, Cuevas C, Dadoun O, Dale D, Dong H, Dumas J, Fanchini E, Forest T, Forman E, Freyberger A, Froidefond E, Golge S, Grames J, Guèye P, Hansknecht J, Harrell P, Hoskins J, Hyde C, Josey B, Kazimi R, Kim Y, Machie D, Mahoney K, Mammei R, Marton M, McCarter J, McCaughan M, McHugh M, McNulty D, Mesick KE, Michaelides T, Michaels R, Moffit B, Moser D, Muñoz Camacho C, Muraz JF, Opper A, Poelker M, Réal JS, Richardson L, Setiniyaz S, Stutzman M, Suleiman R, Tennant C, Tsai C, Turner D, Ungaro M, Variola A, Voutier E, Wang Y, Zhang Y. Production of Highly Polarized Positrons Using Polarized Electrons at MeV Energies. Phys Rev Lett 2016; 116:214801. [PMID: 27284661 DOI: 10.1103/physrevlett.116.214801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Indexed: 06/06/2023]
Abstract
The Polarized Electrons for Polarized Positrons experiment at the injector of the Continuous Electron Beam Accelerator Facility has demonstrated for the first time the efficient transfer of polarization from electrons to positrons produced by the polarized bremsstrahlung radiation induced by a polarized electron beam in a high-Z target. Positron polarization up to 82% have been measured for an initial electron beam momentum of 8.19 MeV/c, limited only by the electron beam polarization. This technique extends polarized positron capabilities from GeV to MeV electron beams, and opens access to polarized positron beam physics to a wide community.
Collapse
Affiliation(s)
- D Abbott
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Adderley
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Adeyemi
- Hampton University, Hampton, Virginia 23668, USA
| | - P Aguilera
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ali
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Areti
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Baylac
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - J Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G Bosson
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - B Cade
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L S Cardman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Clark
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Cole
- Idaho State University, Pocatello, Idaho 83209, USA
| | - S Covert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Cuevas
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Dadoun
- LAL, Université Paris-Sud & Université Paris-Saclay, CNRS/IN2P3, 91898 Orsay, France
| | - D Dale
- Idaho State University, Pocatello, Idaho 83209, USA
| | - H Dong
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Dumas
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - E Fanchini
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - T Forest
- Idaho State University, Pocatello, Idaho 83209, USA
| | - E Forman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Freyberger
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Froidefond
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - S Golge
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Grames
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Guèye
- Hampton University, Hampton, Virginia 23668, USA
| | - J Hansknecht
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Harrell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Hoskins
- The College of William & Mary, Williamsburg, Virginia 23187, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - B Josey
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - R Kazimi
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Kim
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Idaho State University, Pocatello, Idaho 83209, USA
| | - D Machie
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mahoney
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Mammei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Marton
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - J McCarter
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M McHugh
- The George Washington University, Washington, DC 20052, USA
| | - D McNulty
- Idaho State University, Pocatello, Idaho 83209, USA
| | - K E Mesick
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
| | - T Michaelides
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Moffit
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Moser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Muñoz Camacho
- IPN, Université Paris-Sud & Université Paris-Saclay, CNRS/IN2P3, 91406 Orsay, France
| | - J-F Muraz
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - A Opper
- The George Washington University, Washington, DC 20052, USA
| | - M Poelker
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J-S Réal
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - L Richardson
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Setiniyaz
- Idaho State University, Pocatello, Idaho 83209, USA
| | - M Stutzman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Suleiman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Tennant
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Tsai
- Virginia Polytechnique Institut and State University, Blacksburg, Virginia 24061, USA
| | - D Turner
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ungaro
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Variola
- LAL, Université Paris-Sud & Université Paris-Saclay, CNRS/IN2P3, 91898 Orsay, France
| | - E Voutier
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
- IPN, Université Paris-Sud & Université Paris-Saclay, CNRS/IN2P3, 91406 Orsay, France
| | - Y Wang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Zhang
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
| |
Collapse
|
10
|
Secheresse T, Mampe-Armstrong H, Usseglio P, Jorioz C, Bonnet-Gonnet JF, Dumas J. Le débriefing postsimulation en santé. Que nous apprend-il et comment ? Réanimation 2016. [DOI: 10.1007/s13546-015-1154-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Plaweski S, Tchouda SD, Dumas J, Rossi J, Moreau Gaudry A, Cinquin P, Bosson JL, Merloz P. Evaluation of a computer-assisted navigation system for anterior cruciate ligament reconstruction: prospective non-randomized cohort study versus conventional surgery. Orthop Traumatol Surg Res 2012; 98:S91-7. [PMID: 22922105 DOI: 10.1016/j.otsr.2012.07.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Accepted: 07/11/2012] [Indexed: 02/02/2023]
Abstract
BACKGROUND Conventional reconstruction of the anterior cruciate ligament (ACL) is associated with a 15% failure rate. Computer-assisted navigation systems (CANS) have been developed to improve the accuracy of tunnel positioning. HYPOTHESIS The use of a CANS for ACL reconstruction decreases the rate of failure, defined as IKDC grade C or D, compared to conventional ACL reconstruction. MATERIALS AND METHODS This prospective multicentre observational non-randomised open study compared two groups of patients requiring arthroscopic ACL reconstruction: one group was managed with a CANS and the other (control group) without a CANS. The primary evaluation criterion was based on the subjective and objective IKDC scores. Inclusion criteria were age older than 18 years and first ACL reconstruction procedure using autologous semitendinosus and gracilis tendons or an autologous bone-patellar tendon-bone graft. Of the 272 included patients, 214 were analysed; 100 were in the control group and 114 in the CANS group. RESULTS No significant between-group differences were found for the fraction of patients having an IKDC grade A or B (P=0.953), the subjective IKDC score (P=0.77), differential knee laxity at 150 N (1.38 ± 1.79 mm in the control group and 1.77 ± 2.06 mmin the CANS group, P=0.384), graft-type, or graft positioning. DISCUSSION Our results establish the large-scale feasibility of computer-assisted navigation for ACL reconstruction. However, the main outcomes at 1 year showed no significant differences between patients managed with and without computer-assisted navigation.
Collapse
Affiliation(s)
- S Plaweski
- CAOS France, Orthopaedic Surgery and Sports Medicine Academic unit, Academic Department of Orthopaedic Surgery and traumatology, Southern Grenoble Teaching Hospital Center, 38434 Echirolles, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Flecher X, Dumas J, Argenson JN. Is a hip distractor useful in the arthroscopic treatment of femoroacetabular impingement? Orthop Traumatol Surg Res 2011; 97:381-8. [PMID: 21530440 DOI: 10.1016/j.otsr.2011.02.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2010] [Revised: 01/26/2011] [Accepted: 02/04/2011] [Indexed: 02/02/2023]
Abstract
INTRODUCTION There is increasing interest in using hip arthroscopy for the treatment of femoroacetabular impingement (FAI). However, the distraction is typically done with a traction table, which can lead to complications. Our working hypothesis was that a hip-specific distractor could be used to perform arthroscopic treatment of FAI without the complications associated with traction. MATERIAL AND METHODS Twenty-three patients were included in this prospective study with an average follow-up of 21 months (range 12-28 months). The average age was 34 ± 4 years. The technical feasibility, complications, quality of the distraction and early clinical results were evaluated. RESULTS None of the arthroscopy procedures had to be converted to an arthrotomy. In all cases, the procedures planned for the central and peripheral compartments were fully executed. One patient (4%) had a grade 1 cartilage iatrogenic injury of the femoral head. The distraction was determined to be effective in all the patients, with an average of 15 mm of distraction achieved (range 12-21 mm). The average Merle d'Aubigne score went from 11 (range 9-18) preoperatively to 16 (range 14-18) postoperatively; the average Harris score went from 76 (range 46-80) to 91 (range 87-100); the average Christensen score went from 64 (range 48-88) to 84 (range 72-100); the average Womac score went from 58 (range 42-96) to 84 (range 74-100). No neurological, infectious or bone complications were recorded. DISCUSSION The use of a distractor during hip arthroscopy appears to be a reliable and reproducible technique that allows FAI to be treated. Early results are consistent with those reported in the literature, and the risks associated with the use of a traction table are reduced. This technique makes hip arthroscopy safer and contributes to advances in labrum and cartilage repair, without additional complications. LEVEL OF EVIDENCE Level III prospective study.
Collapse
Affiliation(s)
- X Flecher
- Center for Ostearthritis Surgery, Musculo-skeletal diseases Institute, Department of Orthopaedic Surgery, Sainte-Marguerite Hospital, 270, boulevard Sainte-Marguerite, BP 29, 13274 Marseille cedex 09, France.
| | | | | |
Collapse
|
13
|
Latrasse L, Marie-Jeanne M, Lamy T, Thuillier T, Giraud J, Fourel C, Trophime C, Debray F, Sala P, Dumas J. SEISM: a 60 GHz cusp electron cyclotron resonance ion source. Rev Sci Instrum 2010; 81:02A324. [PMID: 20192345 DOI: 10.1063/1.3267297] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
LPSC has been involved for several years in a challenging research and development program on the production of pulsed ions beams with high ionization efficiency primarily dedicated to radioactive ion beams. The generation of the high magnetic field requires the use of helix techniques developed at Laboratoire National des Champs Magnétiques Intenses. As a first approach, a cusp structure has been chosen. 3D simulations were used to define the geometry of the helices. The computer aided design of the mechanical parts of the magnetic structure has been performed at LPSC and was optimized to decrease the total volume of the source. The first 60 GHz magnetic structure (helices coils in their tanks, electrical, and water cooling environment) should be available before the end of 2009.
Collapse
Affiliation(s)
- L Latrasse
- Laboratoire de Physique Subatomique et de Cosmologie, Université Joseph Fourier, CNRS/IN2P3, Institut National Polytechnique de Grenoble, 53 rue des Martyrs F-38026 Grenoble Cedex, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Wells R, Dywan J, Dumas J. Life satisfaction and distress in family caregivers as related to specific behavioural changes after traumatic brain injury. Brain Inj 2009; 19:1105-15. [PMID: 16286324 DOI: 10.1080/02699050500150062] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PRIMARY OBJECTIVE To predict long-term outcome of those caring for family members who have sustained a traumatic brain injury (TBI). METHODS AND PROCEDURES A multivariate approach was used to examine the effectiveness of caregiver coping strategies in the context of TBI-related behavioural change. Self-administered questionnaire packages were collected from 72 adult survivor and family-member pairs who provided information on survivors' altered executive function, behavioural control and emotional sensitivity as well as caregivers' methods of coping, attitudes toward caregiving, indices of distress, mood ratings and quality of life. MAIN OUTCOMES AND RESULTS Family members generally reported higher levels of satisfaction than dissatisfaction with their caregiving role. The type of neurobehavioural deficit and the approaches taken to cope with stress had specific effects on each dimension of caregiver outcome. CONCLUSIONS Adequate family support requires finely tuned assessment of factors relevant to successful coping.
Collapse
Affiliation(s)
- R Wells
- Department of Psychology, Brock University, St. Catharines, Ontario, Canada
| | | | | |
Collapse
|
15
|
Saint-Paul M, Dumas J, Marcus J. Ultrasonic properties near 50 K of the quasi-one-dimensional conductors A(0.30)MoO(3) (A = K, Rb) and Rb(0.30)(Mo(1-x)V(x))O(3). J Phys Condens Matter 2009; 21:215603. [PMID: 21825552 DOI: 10.1088/0953-8984/21/21/215603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The charge density wave (CDW) nonlinear conductivity of the blue bronzes A(0.30)MoO(3) (A = K, Rb) shows two different regimes depending on the temperature: a strongly damped CDW motion above ∼50 K and a CDW motion with almost no damping below ∼50 K. In a search for an elastic signature of this CDW behaviour, we performed ultrasonic measurements on A(0.30)MoO(3) single crystals in the temperature range 4-300 K. In Rb(0.30)MoO(3), at T∼50 K, upon cooling, a large increase of the sound velocity for the longitudinal mode measured along the [Formula: see text], [102] and b directions is observed. The ultrasonic attenuation coefficient shows an increase down to 50 K followed by a plateau. Similar results are found in K(0.30)MoO(3). In V-doped samples, Rb(0.30)(Mo(1-x)V(x))O(3) (x = 0.4%) the anomaly broadens and is shifted towards higher temperatures. The results are discussed in relation to the changes in the CDW rigidity, disorder and dielectric response. A scenario based on a glass transition for the CDW superstructure is proposed.
Collapse
Affiliation(s)
- M Saint-Paul
- Institut Néel, CNRS/UJF, BP 166, F-38042 Grenoble Cedex 9, France
| | | | | |
Collapse
|
16
|
Ravy S, Le Bolloc'h D, Jacques V, Kirova N, Dumas J, Marcus J, Livet F. Observation of micrometric correlations in sliding incommensurate charge-density waves. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308084833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
17
|
Mensah MN, Waugh T, Lavoie R, Dumas J, Bernier M, Garneau MJ, Giroux C, Otis J. "The VIHsibilite Project": HIV-positive people in the Quebec press and community responses. AIDS Care 2008; 20:596-600. [PMID: 18484331 DOI: 10.1080/09540120701867164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The VIHsibilite Project is a community-based action-research initiative that examines newspaper coverage of HIV/AIDS issues in Quebec from 1988 to 2004. Using standard qualitative research methods, and in consultation with an advisory committee of people directly impacted by HIV/AIDS news coverage, the project discerns trends in reporting on HIV/AIDS and undertakes discursive content analysis of these, aiming to better understand in what normative ways seropositive people are represented in print media, and, ultimately, to reduce the stigma attendant upon HIV infection. Preliminary findings include indications that seropositive women tend to be represented markedly differently from men in the news.
Collapse
Affiliation(s)
- M N Mensah
- Ecole de travail social and Institut de recherches et d'études feministes, Université du Québec à Montreal, Succursale Centreville, Montreal, QC, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Souied E, Cohen S, Korobelnik J, Sahel J, Dumas J, Leveziel N, Letien V, Querques G, Renaud M, Coscas G, Soubrane G. 155 Constitution d’une banque d’ADN française de patients atteints de DMLA. J Fr Ophtalmol 2008. [DOI: 10.1016/s0181-5512(08)70751-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Le Bolloc'h D, Jacques VLR, Kirova N, Dumas J, Ravy S, Marcus J, Livet F. Observation of correlations up to the micrometer scale in sliding charge-density waves. Phys Rev Lett 2008; 100:096403. [PMID: 18352733 DOI: 10.1103/physrevlett.100.096403] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2007] [Indexed: 05/26/2023]
Abstract
A high resolution coherent x-ray diffraction experiment has been performed on the charge-density wave (CDW) system K0.3MoO3. The 2kF satellite reflection associated with the CDW has been measured with respect to external dc currents. In the sliding regime, the 2kF satellite reflection displays secondary satellites along the chain axis which corresponds to correlations up to the micrometer scale. This super long-range order is 1500 times larger than the CDW period itself. This new type of electronic correlation seems inherent to the collective dynamics of electrons in charge-density wave systems. Several scenarios are discussed.
Collapse
Affiliation(s)
- D Le Bolloc'h
- Laboratoire de Physique des Solides (CNRS-UMR 8502), Bâtiment 510, Université Paris-sud, 91405 Orsay cedex, France
| | | | | | | | | | | | | |
Collapse
|
20
|
Ron G, Glister J, Lee B, Allada K, Armstrong W, Arrington J, Beck A, Benmokhtar F, Berman BL, Boeglin W, Brash E, Camsonne A, Calarco J, Chen JP, Choi S, Chudakov E, Coman L, Craver B, Cusanno F, Dumas J, Dutta C, Feuerbach R, Freyberger A, Frullani S, Garibaldi F, Gilman R, Hansen O, Higinbotham DW, Holmstrom T, Hyde CE, Ibrahim H, Ilieva Y, de Jager CW, Jiang X, Jones MK, Kang H, Kelleher A, Khrosinkova E, Kuchina E, Kumbartzki G, LeRose JJ, Lindgren R, Markowitz P, May-Tal Beck S, McCullough E, Meekins D, Meziane M, Meziani ZE, Michaels R, Moffit B, Norum BE, Oh Y, Olson M, Paolone M, Paschke K, Perdrisat CF, Piasetzky E, Potokar M, Pomatsalyuk R, Pomerantz I, Puckett A, Punjabi V, Qian X, Qiang Y, Ransome R, Reyhan M, Roche J, Rousseau Y, Saha A, Sarty AJ, Sawatzky B, Schulte E, Shabestari M, Shahinyan A, Shneor R, Sirca S, Slifer K, Solvignon P, Song J, Sparks R, Subedi R, Strauch S, Urciuoli GM, Wang K, Wojtsekhowski B, Yan X, Yao H, Zhan X, Zhu X. Measurements of the proton elastic-form-factor ratio mu pG p E/G p M at low momentum transfer. Phys Rev Lett 2007; 99:202002. [PMID: 18233135 DOI: 10.1103/physrevlett.99.202002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2007] [Indexed: 05/25/2023]
Abstract
High-precision measurements of the proton elastic form-factor ratio, mu pG p E/G p M, have been made at four-momentum transfer, Q2, values between 0.2 and 0.5 GeV2. The new data, while consistent with previous results, clearly show a ratio less than unity and significant differences from the central values of several recent phenomenological fits. By combining the new form-factor ratio data with an existing cross-section measurement, one finds that in this Q2 range the deviation from unity is primarily due to G p E being smaller than expected.
Collapse
Affiliation(s)
- G Ron
- Tel Aviv University, Tel Aviv 69978, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Arnaud A, Crehange G, Brenier J, Dumas J, Truc G, Deville C, Bonnetain F, Lagneau E, Peignaux K, Maingon P. Image-Guided IMRT for Localized Prostatic Carcinoma With Ultrasound-Based Repositioning: Assessing the Difference Between Planned and Delivered Dose Distribution. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21:439-45. [PMID: 17205056 DOI: 10.1038/sj.leu.2404508] [Citation(s) in RCA: 133] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3 tyrosine kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival. We show that sorafenib (BAY 43-9006, Nexavar) potently inhibits FLT3 enzymatic and signaling activities. In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation. In leukemia cell lines MV4-11 and EOL-1, sorafenib treatment resulted in decreased cell proliferation and inhibition of FLT3 signaling. The growth of the FLT3-independent RS4-11 cell line was only weakly inhibited by sorafenib. Cell cycle arrest and induction of apoptosis were observed upon treatment with sorafenib in MV4-11 and EOL-1 cells. The antitumor efficacy of sorafenib was evaluated against the MV4-11 leukemia grown subcutaneously in NCr nu/nu mice. Doses of 3 and 10 mg/kg administered orally for 14 days resulted in six and nine out of 10 animals with complete responses, respectively. The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.
Collapse
Affiliation(s)
- D Auclair
- Department of Cancer Biology, Bayer Pharmaceuticals Corporation, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Plaweski S, Dumas J, Kirshmaier M. 38 Reconstruction du ligament croisé antérieur à un faisceau : évaluation de la laxité antérieure et rotatoire. ACTA ACUST UNITED AC 2006. [DOI: 10.1016/s0035-1040(06)76001-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
24
|
Schlenker C, Dumas J, Escribe-filippini C, Guyot H, Marcus J, Fourcaudot G. Charge-density-wave instabilities in the low-dimensional molybdenum bronzes and oxides. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/13642818508240627] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- C. Schlenker
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| | - J. Dumas
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| | - C. Escribe-filippini
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| | - H. Guyot
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| | - J. Marcus
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| | - G. Fourcaudot
- a Laboratoire d'Etudes des Propriétés Electroniques des Solides, CNRS , BP 166, 38042 , Grenoble , France
| |
Collapse
|
25
|
Duval E, Boukenter A, Achibat T, Champagnon B, Seruchetti J, Dumas J. Structure of silica aerogels and vibrational dynamics in fractal materials and glasses: Electron microscopy and low-frequency Raman scattering. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/13642819208217895] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- E. Duval
- a Laboratoire de Physico-Chimie des Matériaux Luminescents, Unité de Recherche associée au CNRS 442, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| | - A. Boukenter
- a Laboratoire de Physico-Chimie des Matériaux Luminescents, Unité de Recherche associée au CNRS 442, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| | - T. Achibat
- a Laboratoire de Physico-Chimie des Matériaux Luminescents, Unité de Recherche associée au CNRS 442, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| | - B. Champagnon
- a Laboratoire de Physico-Chimie des Matériaux Luminescents, Unité de Recherche associée au CNRS 442, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| | - J. Seruchetti
- b Département de Physique des Matériaux , Unité de Recherche associée au CNRS 172, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| | - J. Dumas
- b Département de Physique des Matériaux , Unité de Recherche associée au CNRS 172, Université Lyon I , Campus de La Doua, F-69622 , Villeurbanne , France
| |
Collapse
|
26
|
Affiliation(s)
- J. Dumas
- a Groupe des Transitions de Phases , C.N.R.S., B.P. 166, 38042 , Grenoble , Cédex , France
| | - C. Schlenker
- a Groupe des Transitions de Phases , C.N.R.S., B.P. 166, 38042 , Grenoble , Cédex , France
| | - R. Buder
- a Groupe des Transitions de Phases , C.N.R.S., B.P. 166, 38042 , Grenoble , Cédex , France
| |
Collapse
|
27
|
Guyot H, Dumas J, Marcus J, Schlenker C, Vignolles D. High magnetic field magnetoresistance anomalies in the charge density wave state of the quasi-two dimensional bronze KMo6O17. ACTA ACUST UNITED AC 2005. [DOI: 10.1051/jp4:2005131066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Le Bolloc'h D, Ravy S, Dumas J, Marcus J, Livet F, Detlefs C, Yakhou F, Paolasini L. Charge density wave dislocation as revealed by coherent x-ray diffraction. Phys Rev Lett 2005; 95:116401. [PMID: 16197025 DOI: 10.1103/physrevlett.95.116401] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2005] [Indexed: 05/04/2023]
Abstract
Coherent x-ray diffraction experiments have been performed on high quality crystals of the charge density wave (CDW) system K0.3MoO3. The satellite reflections associated with the CDW have been measured as a function of the 20-microm-diameter beam position. For some positions, regular fringes have been observed. We show that this observation is consistent with the presence of a single CDW dislocation. Beyond charge density wave systems, this experiment shows that coherent x-ray diffraction is a suitable tool to probe topological defects embedded in the bulk.
Collapse
Affiliation(s)
- D Le Bolloc'h
- Laboratoire de Physique des Solides, CNRS-UMR 8502, Bâtiment 510, Université Paris-sud, 91405 Orsay cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Willer B, Dumas J, Hutson A, Leddy J. A population based investigation of head injuries and symptoms of concussion of children and adolescents in schools. Inj Prev 2004; 10:144-8. [PMID: 15178669 PMCID: PMC1730088 DOI: 10.1136/ip.2003.005017] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To examine the incidence of head injury and symptoms of concussion among children at school and to determine the relationship of age, gender, and cause to incidence rates. DESIGN Incident reports involving head injury for schools in the Province of Ontario, Canada during the year 2000 were evaluated. PARTICIPANTS The population base for the schools represented was 1 372 979 children aged 6 to 16. SETTING 95% of schools in the province of Ontario, Canada participated in the injury reporting system. MAIN OUTCOME MEASURES A head injury was defined as any injury to the head that came to the attention of a school official. Head injuries accompanied by symptoms of concussion became a secondary outcome measure. RESULTS There were 11 068 unduplicated head injury reports for the year 2000 of which 1861 qualified as producing signs or symptoms of concussion. Young children were more likely to have a head injury than older children, but slightly less likely to experience concussive symptoms. The primary cause of injury to young children was falls. Older children were more likely to receive head injuries and symptoms of concussion from sports activities. CONCLUSIONS Overall rate of injury (3.98 per 100 children) was consistent with previous studies using prospective injury reporting systems. Probability of a head injury with symptoms of concussion among schoolchildren was only 1.9% for boys and <1% for girls during the course of their school years. There is ample justification for prevention efforts in schools.
Collapse
Affiliation(s)
- B Willer
- University at Buffalo, Brock University, NY, USA.
| | | | | | | |
Collapse
|
30
|
Sauvage E, Kerff F, Fonzé E, Herman R, Schoot B, Marquette JP, Taburet Y, Prevost D, Dumas J, Leonard G, Stefanic P, Coyette J, Charlier P. The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell Mol Life Sci 2002; 59:1223-32. [PMID: 12222968 DOI: 10.1007/s00018-002-8500-0] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Penicillin-binding proteins (PBPs) are membrane proteins involved in the final stages of peptidoglycan synthesis and represent the targets of beta-lactam antibiotics. Enterococci are naturally resistant to these antibiotics because they produce a PBP, named PBP5fm in Enterococcus faecium, with low-level affinity for beta-lactams. We report here the crystal structure of the acyl-enzyme complex of PBP5fm with benzylpenicillin at a resolution of 2.4 A. A characteristic of the active site, which distinguishes PBP5fm from other PBPs of known structure, is the topology of the loop 451-465 defining the left edge of the cavity. The residue Arg464, involved in a salt bridge with the residue Asp481, confers a greater rigidity to the PBP5fm active site. In addition, the presence of the Val465 residue, which points into the active site, reducing its accessibility, could account for the low affinity of PBP5fm for beta-lactam. This loop is common to PBPs of low affinity, such as PBP2a from Staphylococcus aureus and PBP3 from Bacillus subtilis. Moreover, the insertion of a serine after residue 466 in the most resistant strains underlines even more the determining role of this loop in the recognition of the substrates.
Collapse
Affiliation(s)
- E Sauvage
- Centre d'Ingénierie des Protéines, Université de Liege, Institut de Physique, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Whangbo MH, Koo HJ, Dumas J, Continentino MA. Theoretical investigation of the spin exchange interactions and magnetic properties of the homometallic ludwigite Fe(3)O(2)BO(3). Inorg Chem 2002; 41:2193-201. [PMID: 11952374 DOI: 10.1021/ic010956q] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The homometallic ludwigite Fe(3)O(2)BO(3) has a complex structure made up of corner- and edge-sharing FeO(6) octahedra and exhibits a number of apparently puzzling magnetic properties. The reasons for these properties were probed by examining the trends in the spin exchange interactions of Fe(3)O(2)BO(3). To analyze the relative strengths of spin exchange interactions in such a complex magnetic solid, we first generalized the method of spin dimer analysis and then employed the resulting formulation to investigate how the magnetic properties of Fe(3)O(2)BO(3) are related to its reported crystal structures. The spin-orbital interaction energies calculated for various spin dimers of Fe(3)O(2)BO(3) provide estimates for the relative strengths of the associated spin exchange interactions, which in turn account for the observed magnetic properties of Fe(3)O(2)BO(3).
Collapse
Affiliation(s)
- M-H Whangbo
- Department of Chemistry, North Carolina State University, Raleigh 27695-8204, USA.
| | | | | | | |
Collapse
|
32
|
Smith RA, Bhargava A, Browe C, Chen J, Dumas J, Hatoum-Mokdad H, Romero R. Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett 2001; 11:2951-4. [PMID: 11677133 DOI: 10.1016/s0960-894x(01)00600-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Peptidomimetic aminomethyl ketones have been identified as a new class of cathepsin K inhibitors. Traditional and high-speed parallel synthesis techniques were applied to investigate this series. Structure-activity relationships were established, and certain analogues were characterized with IC(50) values in the range 200-500 nM.
Collapse
Affiliation(s)
- R A Smith
- Department of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA.
| | | | | | | | | | | | | |
Collapse
|
33
|
Dumas J. Growth factor receptor kinase inhibitors: recent progress and clinical impact. Curr Opin Drug Discov Devel 2001; 4:378-89. [PMID: 11727303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Inhibition of growth factor receptor kinases is one of the most promising therapeutic approaches for the treatment of cancer. This review focuses on the most recent progress in this area, and gives an overview of the compounds currently in the clinic, as well as key preclinical analogs.
Collapse
Affiliation(s)
- J Dumas
- Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA.
| |
Collapse
|
34
|
Goirand F, Bardou M, Dumas J, Rochette L, Dumas M. Effects of phosphodiesterase inhibitors on hypoxic pulmonary vasoconstriction. Influence of K(+) channels and nitric oxide. Eur J Pharmacol 2001; 417:141-8. [PMID: 11301069 DOI: 10.1016/s0014-2999(01)00900-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We studied the relaxant effects of the cyclic nucleotide phosphodiesterase inhibitors theophylline (non-selective), rolipram (type IV, 3',5'-cyclic monophosphate (cAMP)-specific) and zaprinast (type V, 3',5'-cyclic monophosphate (cGMP)-specific) on the hypoxic vasoconstriction in the isolated perfused rat lung and the involvement of K(+) channels and nitric oxide (NO) in these effects. K(+) channels were inhibited by glibenclamide, charybdotoxin, apamin and 4-aminopyridine and nitric oxide synthase by L-N(G)-nitroarginine methyl ester (L-NAME). Hypoxic ventilation produced a significant pressure response. L-NAME and 4-aminopyridine increased this response. Rolipram, zaprinast and theophylline shared the ability to oppose the hypoxic pulmonary vasoconstriction. The order of potency was zaprinast>rolipram>theophylline. Glibenclamide partially inhibited the relaxant effects of rolipram and theophylline. Charybdotoxin inhibited the dilator response to rolipram. Apamin inhibited partially the vasodilation induced by rolipram and zaprinast. 4-Aminopyridine inhibited partially the relaxant effects of theophylline. L-NAME failed to block the effects of the three compounds. These data illustrate different pharmacological profiles according to the phosphodiesterase inhibitors and support the potential interest of selective inhibitors as relaxant agents in pulmonary vessels.
Collapse
Affiliation(s)
- F Goirand
- Laboratoire de Physiopathologie et de Pharmacologie Cardiovasculaires Expérimentales, Faculté de Médecine, 7 Bd Jeanne d'Arc, BP 87900, 21079 cedex, Dijon, France.
| | | | | | | | | |
Collapse
|
35
|
Abstract
This work aims at representing empirical knowledge of freshwater ecologists on the functioning of salmon redds (spawning areas of salmon) and its impact on mortality of early stages. For this, we use Qsim, a qualitative simulator. In this first part, we provide unfamiliar readers with the underlying qualitative differential equation (QDE) ontology of Qsim: representing quantities, qualitative variables, qualitative constraints, QDE structure. Based on a very simple example taken of the salmon redd application, we show how informal biological knowledge may be represented and simulated using an approach that was first intended to analyze qualitatively ordinary differential equations systems. A companion paper (Part II) gives the full description and simulation of the salmon redd qualitative model. This work was part of a project aimed at assessing the impact of the environment on salmon populations dynamics by the use of models of processes acting at different levels: catchment, river, and redds. Only the latter level is dealt with in this paper.
Collapse
Affiliation(s)
- F Guerrin
- Inra, Unité de Biométrie et Intelligence artificielle, BP 27, 31326 Castanet-Tolosan Cedex, France.
| | | |
Collapse
|
36
|
|
37
|
Abstract
This paper describes a qualitative model of the functioning of salmon redds (spawning areas of salmon) and its impact on mortality rates of early stages. For this, we use Qsim, a qualitative simulator, which appeared adequate for representing available qualitative knowledge of freshwater ecology experts (see Part I of this paper). Since the number of relevant variables was relatively large, it appeared necessary to decompose the model into two parts, corresponding to processes occurring at separate time-scales. A qualitative clock allows us to submit the simulation of salmon developmental stages to the calculation of accumulated daily temperatures (degree-days), according to the clock ticks and a water temperature regime set by the user. Therefore, this introduces some way of real-time dating and duration in a purely qualitative model. Simulating both sub-models, either separately or by means of alternate transitions, allows us to generate the evolutions of variables of interest, such as the mortality rates according to two factors (flow of oxygenated water and plugging of gravel interstices near the bed surface), under various scenarios.
Collapse
Affiliation(s)
- F Guerrin
- Inra, Unité de Biométrie et Intelligence artificielle, BP 27, 31326 Castanet-Tolosan Cedex, France.
| | | |
Collapse
|
38
|
Redman AM, Johnson JS, Dally R, Swartz S, Wild H, Paulsen H, Caringal Y, Gunn D, Renick J, Osterhout M, Kingery-Wood J, Smith RA, Lee W, Dumas J, Wilhelm SM, Housley TJ, Bhargava A, Ranges GE, Shrikhande A, Young D, Bombara M, Scott WJ. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorg Med Chem Lett 2001; 11:9-12. [PMID: 11140741 DOI: 10.1016/s0960-894x(00)00574-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
Collapse
Affiliation(s)
- A M Redman
- Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Larivière C, Gagnon D, Gravel D, Dumas J, Goyette M, Loisel P. A triaxial dynamometer to monitor lateral bending and axial rotation moments during static trunk extension efforts. Clin Biomech (Bristol, Avon) 2001; 16:80-3. [PMID: 11114447 DOI: 10.1016/s0268-0033(00)00068-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE The purpose of the study was to describe a new static triaxial dynamometer designed to monitor the lateral bending and axial rotation moments during trunk extension efforts. BACKGROUND Most studies on back muscle function using electromyographic spectral analysis have not controlled moments produced about the three orthopaedic axes during trunk extension efforts. Criteria to control lateral bending and axial rotation moments during extension efforts have not been proposed in the literature. METHODS Fourteen healthy subjects performed three trunk extension ramp contractions (0-100% of the maximal voluntary contraction). Triaxial L5/S1 moments at 20%, 40%, 60% and 80% of the maximal voluntary contraction in extension were extracted. RESULTS During the extension efforts, the lateral bending and axial rotation moments at L5/S1 increased significantly across the force levels and reached 6.2 Nm (SD: 6.6) and 6.1 Nm (SD: 4.5), respectively, at 80% of the maximal voluntary contraction. Tolerance limits were proposed to control these associated efforts in the context of the electromyographic analysis of back muscles. Relevance. Simultaneous measurement of lateral bending and axial rotation moments at L5/S1 during extension efforts might help to explain and control load sharing between back muscles during extension efforts.
Collapse
Affiliation(s)
- C Larivière
- Research Center, Montreal Rehabilitation Institute, Que., Montreal, Canada
| | | | | | | | | | | |
Collapse
|
40
|
Boukenter A, Champagnon B, Duval E, Rousset JL, Dumas J, Serughetti J. Vibrational modes in silica aerogels: low-frequency Raman scattering. ACTA ACUST UNITED AC 2000. [DOI: 10.1088/0022-3719/21/34/001] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
41
|
Dumas J, Sibley R, Riedl B, Monahan MK, Lee W, Lowinger TB, Redman AM, Johnson JS, Kingery-Wood J, Scott WJ, Smith RA, Bobko M, Schoenleber R, Ranges GE, Housley TJ, Bhargava A, Wilhelm SM, Shrikhande A. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett 2000; 10:2047-50. [PMID: 10999467 DOI: 10.1016/s0960-894x(00)00270-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The MAP kinase p38 has been implicated in cytokine signaling, and its inhibitors are potentially useful for the treatment of arthritis and osteoporosis. Novel small-molecule inhibitors of p38 kinase were derived from a combinatorial chemistry effort and exhibit activity in the nanomolar range. Very steep structure-activity relationships are observed within this class.
Collapse
Affiliation(s)
- J Dumas
- Department of Chemistry Research, Bayer Research Center, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Dumas J, Hatoum-Mokdad H, Sibley R, Riedl B, Scott WJ, Monahan MK, Lowinger TB, Brennan C, Natero R, Turner T, Johnson JS, Schoenleber R, Bhargava A, Wilhelm SM, Housley TJ, Ranges GE, Shrikhande A. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg Med Chem Lett 2000; 10:2051-4. [PMID: 10999468 DOI: 10.1016/s0960-894x(00)00272-9] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-molecule inhibitors of p38 by a combinatorial chemistry effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50 = 13 nM).
Collapse
Affiliation(s)
- J Dumas
- Department of Chemistry Research, Bayer Research Center, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
[reaction: see text] An efficient method for the preparation of 3-aminofuran-2-carboxylate esters has been developed. This method is based on the reaction of an alpha-cyanoketone with ethyl glyoxylate under Mitsunobu conditions to produce a vinyl ether in good yield. Subsequent treatment of the vinyl ether with sodium hydride afforded the 3-aminofuran. It was also found that a one-pot procedure using the Mitsunobu reaction followed by cyclization afforded the 3-aminofuran in comparable yield. Currently, this method is limited to the synthesis of 5-alkyl-, 5-aryl-, and 4,5-fused bicyclic furans.
Collapse
Affiliation(s)
- A M Redman
- Department of Chemistry Research, Bayer Research Center, West Haven, Connecticut 06516, USA.
| | | | | |
Collapse
|
44
|
Cochrane J, Goering P, Durbin J, Butterill D, Dumas J, Wasylenki D. Tertiary mental health services: II. Subpopulations and best practices for service delivery. Can J Psychiatry 2000; 45:185-90. [PMID: 10742879 DOI: 10.1177/070674370004500210] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tertiary care subpopulations are characterized by having more than one significant condition, each of which has been traditionally dealt with by different systems of care. They experience severe and persistent mental illness and one or more of the following: age-related physical or medical conditions, substance use disorders, developmental handicaps, and acquired brain injury. This paper provides estimates of prevalence for each of these subgroups and discusses best practices which have developed in response to their special needs.
Collapse
Affiliation(s)
- J Cochrane
- Centre for Addiction & Mental Health, Clarke Division, Toronto, Ontario
| | | | | | | | | | | |
Collapse
|
45
|
Dumas J, Brittelli D, Chen J, Dixon B, Hatoum-Mokdad H, König G, Sibley R, Witowsky J, Wong S. Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett 1999; 9:2531-6. [PMID: 10498202 DOI: 10.1016/s0960-894x(99)00433-3] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Cathepsin D, a lysosomal aspartyl protease, has been implicated in the pathology of Alzheimer's disease as well as breast and ovarian cancer. A weakly active cathepsin D inhibitor was identified by high throughput screening. Subsequent optimization led to the discovery of a new class of small molecule inhibitors of this enzyme, culminating with the sulfonamide 13 (IC50 = 250 nM).
Collapse
Affiliation(s)
- J Dumas
- Department of Chemistry Research, Bayer Corporation, West Haven, CT 06516, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Hamroun D, Dumas J, Mathieu MN, Launay JM, Chevillard C. Phosphoramidon-sensitive and -insensitive endothelin-converting enzyme in human megakaryoblastic cell lines. J Cardiovasc Pharmacol 1998; 31 Suppl 1:S512-4. [PMID: 9595528 DOI: 10.1097/00005344-199800001-00147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The human megakaryoblastic cell lines HEL, MEG-01, and DAMI express preproendothelin-1 mRNA. This investigation was designed to find out whether they could also express endothelin-converting enzyme (ECE) and release mature endothelin (ET). RT-PCR applied to RNA isolated from the cell lines amplified fragments of the expected size. The amplified cDNA of MEG-01 was submitted to restriction enzymes, which generated the expected subfragments. Membrane ECE activity was phosphoramidon-sensitive, in contrast to the cytosolic activity capable of producing ET-1 from big ET-1. The three cell lines produced ir-ET in a time-dependent manner. These results show that human megakaryoblastic cell lines express functional, phosphoramidon-sensitive and insensitive ECE activity and produce mature ET.
Collapse
|
47
|
Abstract
OBJECTIVE To study the effect of patching on the speed of reepithelialization, slit-lamp signs of epithelial wound healing, and patient discomfort following a corneal abrasion. METHODS Forty-eight eyes of 46 patients with corneal erosion sparing Bowman membrane were randomized into 2 groups: with or without patching. Slit-lamp examination and photographs of the fluorescein-stained cornea were performed on a daily basis until reepithelialization was complete. Photographs were analyzed using computer-assisted planimetry. RESULTS No statistically significant difference was found between patched (n = 25) and nonpatched (n = 22) eyes for the mean size of the initial erosion (patched eyes, 23.7 mm2; nonpatched eyes, 18.9 mm2; P = .42), linear speed of reepithelialization (reduction over time of the radius of the largest circle included in the erosion: patched eyes, 0.0375 mm/h; nonpatched eyes, 0.0353 mm/h; P = .78), and surface speed of reepithelialization (reduction over time of the erosion area: patched eyes, 0.6510 mm2/h; nonpatched eyes, 0.5657 mm2/h; P = .60). The power to detect a 12-hour delay of epithelial closure was 95%. There were no significant differences between the 2 groups for pain, analgesia, insomnia, aspect of the epithelial border, intensity and duration of stromal edema, Descemet folds, anterior uveitis, and filaments. CONCLUSIONS Patching a corneal erosion does not significantly accelerate reepithelialization and does not alter the epithelial wound healing pattern. It does not reduce the incidence and severity of inflammation nor relieve pain when compared with treatment without patching.
Collapse
Affiliation(s)
- J D Arbour
- Department of Ophthalmology, University of Montreal, Quebec
| | | | | | | | | | | |
Collapse
|
48
|
Aubin P, Le Brun G, Moldovan F, Villette JM, Créminon C, Dumas J, Homyrda L, Soliman H, Azizi M, Fiet J. Sandwich-type enzyme immunoassay for big endothelin-I in plasma: concentrations in healthy human subjects unaffected by sex or posture. Clin Chem 1997; 43:64-70. [PMID: 8990224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A sandwich-type enzyme immunoassay has been developed for measuring human big endothelin-1 (big ET-1) in human plasma and supernatant fluids from human cell cultures. Big ET-1 is the precursor of endothelin 1 (ET-1), the most potent vasoconstrictor known. A rabbit antibody raised against the big ET-1 COOH-terminus fragment was used as an immobilized antibody (anti-P16). The Fab' fragment of a monoclonal antibody (1B3) raised against the ET-1 loop fragment was used as the enzyme-labeled antibody, after being coupled to acetylcholinesterase. The lowest detectable value in the assay was 1.2 pg/mL (0.12 pg/well). The assay was highly specific for big ET-1, demonstrating no cross-reactivity with ET-1, <0.4% cross-reactivity with big endothelin-2 (big ET-2), and <0.1% with big endothelin-3 (big ET-3). We used this assay to evaluate the effect of two different postural positions (supine and standing) on plasma big ET-1 concentrations in 11 male and 11 female healthy subjects. Data analysis revealed that neither sex nor body position influenced plasma big ET-1 concentrations. This assay should thus permit the detection of possible variations in plasma concentrations of big ET-1 in certain pathologies and, in association with ET-1 assay, make possible in vitro study of endothelin-converting enzyme activity in cell models. Such studies could clarify the physiological and clinical roles of this family of peptides.
Collapse
Affiliation(s)
- P Aubin
- Laboratoire de Biologie Hormonale, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Thrane BP, Schlenker C, Dumas J, Buder R. Angular dependence of the irreversible magnetization of YBa2Cu3O7 superconducting thin films. Phys Rev B Condens Matter 1996; 54:15518-15524. [PMID: 9985621 DOI: 10.1103/physrevb.54.15518] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
50
|
Hess C, Schlenker C, Dumas J, Greenblatt M, Teweldemedhin ZS. Magnetotransport and thermopower properties of the quasi-two-dimensional charge-density-wave compounds (PO2)4 (WO3)2m (m=4,6). Phys Rev B Condens Matter 1996; 54:4581-4588. [PMID: 9986416 DOI: 10.1103/physrevb.54.4581] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|